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The identification of tau protein as a major constituent of neurofibrillary tangles spurred considerable effort devoted
to identifying and validating pathways through which therapeutics may alleviate tau burden in Alzheimer’s disease
and related tauopathies, including chronic traumatic encephalopathy associated with sport- and military-related
injuries. Most tau-based therapeutic strategies have previously focused on modulating tau phosphorylation, given
that tau species present within neurofibrillary tangles are hyperphosphorylated on a number of different residues.
However, the recent discovery that tau is modified by acetylation necessitates additional research to provide greater
mechanistic insight into the spectrum of physiological consequences of tau acetylation, which may hold promise as
a novel therapeutic target. In this review, we discuss recent findings evaluating tau acetylation in the context of
previously accepted notions regarding tau biology and pathophysiology. We also examine the evidence
demonstrating the neuroprotective and beneficial consequences of inhibiting histone deacetylase (HDAC)6, a tau
deacetylase, including its effect on microtubule stabilization. We also discuss the rationale for pharmacologically
modulating HDAC6 in tau-based pathologies as a novel therapeutic strategy.Introduction
The identification of tubulin as the first cytosolic protein
to be modified by acetylation [1,2] challenged the trad-
itional notion that acetylation only serves as a mechanism
to regulate transcription through modification of histones.
Since this discovery in 1985, researchers have sought to
identify other proteins that undergo acetylation events
and elucidate the effects of this post-translational modifi-
cation on protein structure and function. Global proteomic
studies allowed for the identification of hundreds of
proteins that are acetylated on one or multiple lysine
residues, as well as a myriad of lysine acetyltransferases
and deacetylases, which respectively govern protein
acetylation and deacetylation [1,3]. The discovery that
the microtubule-associated protein tau is also a target of
acetyltransferase and deacetylase enzymes [4,5] added a
new layer of complexity, whereby the impact of phos-
phorylation or ubiquitination on tau function and biology
will now need to be re-evaluated to include consideration
of tau acetylation. The purpose of the current review is to
discuss the recent findings associated with tau acetyl-
ation, a novel post-translational modification of tau, how* Correspondence: Petrucelli.leonard@mayo.edu
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2014it influences tau aggregation and function, and whether
it could be exploited therapeutically as a treatment for
tauopathies.
The impact of tau acetylation on its propensity to
aggregate
As lysine residues are unique in their ability to partici-
pate in electrostatic and hydrophobic interactions [6,7],
and are also known to play a critical role in tau assembly
and toxicity [8-10], we and others recently questioned
whether tau acetylation of lysine residues would
modulate its potential to aggregate [4,11]. Cohen and
collagues [4] utilized the acetyltransferase CREB-
binding protein (CBP) to acetylate a fragment of tau
comprising the microtubule-binding domain (commonly
referred to as K18), and observed an increase in aggrega-
tion of the K18 fragment. We subsequently performed a
similar analysis but using full-length tau and the acetyl-
transferase p300; we detected a decrease in filament
assembly following tau acetylation, the extent of which
correlated with the concentration of p300 [11]. We also
observed a complete reversal of p300-mediated acety-
lation and inhibition of tau assembly upon addition of
the deacetylase histone deacetylase (HDAC)6 [11]. Fur-
thermore, the modulation of tau assembly by acetylationThe licensee has exclusive rights to distribute this article, in any medium, for 12
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the microtubule-binding domain, as evidenced by the
fact pseudoacetylation of the four KXGS motifs gener-
ated a tau species that was assembly-incompetent and
resistant to modulation by either p300 or HDAC6 [11].
The results from these two studies suggest that CBP and
p300 may preferentially acetylate different residues in
tau, thereby differentially impacting tau’s intrinsic pro-
pensity to aggregate.
Cohen and colleagues [12] later reported that tau can
be acetylated in the absence of the enzyme CBP, an
effect attributed to a previously unrecognized role of
tau as an acetyltransferase enzyme. Cys291 and Cys322
were identified as the catalytic residues responsible for
this novel function of tau [12]. We have not observed
acetylation of full-length tau in the absence of an
exogenous acetyltransferase enzyme [11], indicating
that certain experimental conditions, but not all, favor
nonenzymatic acetylation [4,12-14]. It is worth noting
that nonenzymatic acetylation of cysteine residues has
been reported [15], raising the possibility that the in-
crease in tau assembly following acetylation observed
by the Cohen group could be due to the modification
of amino acid residues other than lysine. Future studies
to delineate the physiological consequences of tau
acetylation in a site-specific manner and to map the
pattern of acetylation produced by different acetyl-
transferase and deacetylase enzymes are therefore
imperative.Figure 1 Schematic diagram of the tau protein with post-translationa
tau (4R2N) are depicted, which includes two amino-terminal inserts (N1 a
post-translational modifications above the tau molecule depict phosphor
pathological tau species purified from Alzheimer’s disease brain [38]. The
residues that are acetylated by both p300 and CREB-binding protein (blac
(green font) [4].Interplay between post-translational modifica-
tions on tau
The multitude of molecular and functional properties of
the microtubule-associated protein tau are predomin-
antly due to the protein’s natively unfolded structure,
allowing tau to not only interact with a large number
of other cellular proteins, but also undergo a variety of
post-translational modifications [16]. The occurrence
of several post-translational modifications on numerous
proteins has been well described, and it has been postu-
lated that the interaction of such modifications governs
complex regulatory processes, which are essential for
proper protein function and for the regulation of diverse
cellular events [3]. While each post-translational modifi-
cation is distinct and utilizes different chemical groups
to modify a given protein on specific residues, a certain
degree of overlap exists [3,17]. For instance, lysine
residues are targets for acetylation events and other
modifications, including ubiquitination, sumoylation and
methylation [3]. Thus, a measure of rivalry between dif-
ferent post-translational modifications must exist, where
the addition of one chemical group to a given residue
precludes further modifications [3].
Intense investigation into the role of post-translational
modifications, specifically phosphorylation and acety-
lation, has now begun, driven by the potential implica-
tions of these modifications in Alzheimer’s disease (AD)
and other tauopathies [4,11,16,18,19] (Figure 1). Tau’s
function as a phosphoprotein is attributed to its 85l modification sites. The molecular domains of the longest isoform of
nd N2) and four microtubule-binding domain repeats (R1 to R4). The
ylation (black font) and ubiquitination (red font) sites observed in
post-translational modifications below the tau molecule illustrate the
k font) [4,5], only p300 (blue font) [5], or only CREB-binding protein
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located in the proline-rich domain and the carboxy-
terminal region of the protein flanking tau’s microtubule-
binding domains [18,19]. Of these sites, approximately 20
serine and threonine residues have been found to be asso-
ciated with normal, physiologically important phosphoryl-
ation events [20,21]. In addition, it is well-documented
that the phosphorylation status of tau is developmentally
regulated, with higher phosphorylation levels being
present during early developmental stages of the brain
compared to the mature, adult brain [16,19,22]. These
findings imply that tau phosphorylation is a dynamic,
highly regulated process, requiring the precise interplay
of a multitude of kinases and phosphatases [18,22]. Because
hyperphosphorylation of tau stimulates polymerization
and accumulation in the form of insoluble neurofibrillary
tangles (NFTs) [18,22,23], research has primarily focused
on elucidating the underlying cause of aberrant tau phos-
phorylation and the effects of this post-translational
modification on tau function. While the precise mecha-
nisms underlying the formation of these characteristic
neuropathological lesions remain to be fully elucidated,
studies have implicated dysregulation of the many kinases
and phosphatases that govern tau phosphorylation
[16,18,22]. For example, all six isoforms of human tau are
constituents of paired helical filaments (PHFs), with all
isoforms abnormally hyperphosphorylated [18] in post-
mortem brain tissue from AD patients. In addition, tau
hyperphosphorylation has been reported to lead to con-
formational changes that decrease flexibility and affinity
for microtubules, thereby promoting accumulation of tau
in the cytosol and driving the formation of PHFs and
NFTs [18,24]. The polymerization and accumulation of
hyperphosphorylated tau (p-tau) has also been linked
with impaired axonal transport and synaptic dysfunction,
two early events associated with the neuronal degener-
ation observed in AD and other tauopathies [18,25].
Understanding the precise molecular mechanisms under-
lying this pathological alteration of tau is critical to
identify novel and effective neurotherapeutics for the
treatment of AD and other tauopathies.
Acetylation as a novel post-translational modification
of tau was first described by Min and colleagues [5],
who used synthetic peptides spanning amino acids 160
to 182 and 264 to 287 of the full-length (4R2N isoform)
tau sequence to generate acetylated-tau antibodies. With
these antibodies (referred to as Ab708 and 9AB), sirtuin
1 (SIRT1) was identified as the deacetylase for the acety-
lation sites contained within amino acids 160 to 182
(Ab708) and 264 to 287 (9AB) [5]. Based on these results,
the authors proposed a model whereby the deacetylase
activity of SIRT1 promotes the removal of acetyl groups
from tau, thus allowing for the addition of ubiquitin to
these freed lysine residues and subsequently enhancingtau’s proteasomal turnover [5]. This model speaks to the
previously addressed complexity associated with post-
translational modifications of tau, and underscores that
we are still at the beginning of understanding which en-
zymes regulate tau acetylation and deacetylation events,
and more specifically how tau modifications associated
with acetylation govern tau biology.
The discovery that tau is modified by acetylation [5]
has since prompted new research efforts primarily fo-
cused on assessing the pathological significance of this
novel aspect of tau biology [4,5,26,27]. Specifically, Irwin
and associates [27] generated a novel antibody detecting
acetylation of tau at K280, and concluded that tau acety-
lated at this epitope colocalized with other classical
markers of tau pathology, with colocalization being most
prominent in moderate to severe disease stages. Given
that acetylation of tau at K280 is highest at late stages of
disease, it is possible increased acetylation at this epitope
is a response to the disease process, rather than a patho-
genic mechanism responsible for tangle formation. In a
subsequent report, Grinberg and colleagues [26] focused
on a different tau acetylation site, and developed an anti-
body to detect acetylation on K274. Although enhanced
acetylation of tau on this epitope was observed in most
tauopathies, the authors detected a lack of tau acety-
lation on K274 in the tauopathy agyrophilic grain disease
[26]. As such, it is evident that additional research evalu-
ating tau acetylation is needed to elucidate differences
that may be attributed to site and disease.
The discovery of tau acetylation also prompted efforts
in our own lab to elucidate whether HDAC6 activity
modulates tau’s pathogenicity directly through tau deace-
tylation [11,28]. We demonstrate that elevated HDAC6
activity increases phosphorylation of tau at the 12E8
epitope (pS262/356), a phospho-epitope present within
the KXGS motifs of tau’s microtubule-binding domain.
The phosphorylation of KXGS motifs within tau by the
kinase Par-1/MARK2 is required for tau proteotoxicity in
Drosophila [29], observed at very early stages of NFT
formation in AD brain [30], and appears to prime tau for
subsequent phosphorylation events [29,31]. Tau species
phosphorylated on KXGS motifs are not recognized by
cellular degradation machinery, including the tau ubiqui-
tin ligase C-terminus of Hsc70 interacting protein (CHIP)
and the heat shock protein 70/90 (Hsp70/90) chaperone
complex [32,33], and are therefore particularly prone to
accumulate. Of note, the synaptic toxicity of oligomeric
amyloid beta is dependent upon the phosphorylation of
tau’s KXGS motifs [34,35], providing additional support
for a pathogenic role of this phospho-tau species. Given
that tau species phosphorylated on KXGS motifs are
resistant to degradation and accumulate in NFTs [30],
fail to bind and stabilize microtubules [36], and are also
primed for phosphorylation by other kinases [29,31],
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erably enhance tau pathology. We recently demonstrated
that, in addition to modulating phosphorylation at these
critical KXGS motif regions, HDAC6 also regulates their
acetylation [11]. As mentioned above, this acetylation
decreases the ability of tau to aggregate in in vitro assays
[11]. We also detect a competitive relationship between
acetylation and phosphorylation on KXGS motifs, such
that treatment with HDAC6 inhibitors simultaneously
increases acetylation of tau, while blocking phosphoryl-
ation at these crucial motifs in mice [11]. Furthermore,
KXGS motifs are hypoacetylated and hyperphosphory-
lated in patients with AD and in a progressive and
well-characterized mouse model of tauopathy (rTg4510)
[11,37]. The link between a loss of acetylation on KXGS
motifs and disease pathogenesis is further strengthened
by the observation that KXGS motifs are ubiquitinated
in pathological tau purified from post-mortem human
brain tissue in AD [38] (Figure 1), thereby indicating such
ubiquitination would preclude another post-translational
modification, acetylation, from occurring.
Overall, these results highlight the extreme complexity
of post-translational modifications governing tau function,
and illustrate the need for improved understanding of
how modified tau species impact neuronal health. Given
that HDAC6 had no effect on the acetylation of residues
recognized by the Ab708 antibody [5], and that we re-
cently demonstrated that deacetylation of KXGS motifs
is mediated by HDAC6 and not SIRT1 [11], the pattern
of tau acetylation is determined by more than one deace-
tylase. Future studies will be required to map the specific
acetylation sites regulated by different deacetylases in
order to determine the ultimate consequence(s) of modu-
lating deacetylase (HDAC6 versus SIRT1) activity on tau
function and biology. Moreover, pathological alterations
of tau are most likely not the result of a single post-
translational modification, but instead a combination of
structural and functional alterations that may ultimately
contribute to determine tau pathogenicity.
Effect of acetylation on tau turnover
Following identification of the tau protein as a major
constituent of NFTs in AD and other tauopathies,
several lines of research focused on identifying the
mechanism(s) responsible for tau accumulation in dis-
ease. Most conducted studies have focused on the effect
of hyperphosphorylation on tau turnover, due to the fact
that hyperphosphorylation has been the first and one
of the most prominent post-translational modifications
associated with tau pathology [33,39-42]. In particular,
previous studies have demonstrated that the tau ubiqui-
tin ligase, CHIP, is unable to bind and ubiquitinate tau
species phosphorylated by Par-1/MARK2 on the 12E8
epitope (S262/356) [33], a p-tau species that is alsoresistant to degradation upon treatment with Hsp90
inhibitors [32,33]. Tau phosphorylated at the PHF1
epitope (S396/404) is still susceptible to degradation
following Hsp90 inhibition and actually exhibits an
enhanced interaction with Hsp90 [33]. These findings
indicate that certain p-tau species, rather than normal
tau, are a preferred client protein of Hsp90, while some
phosphorylation events, in particular those mediated by
Par-1/MARK2 on tau’s KXGS motifs, generate a p-tau
species not recognized by the chaperone network. Phos-
phorylation by Par-1/MARK2 on KXGS motifs in the
microtubule-binding domain of tau has been shown to
be required for initiation of the pathogenic cascade of
hyperphosphorylation, which is ultimately associated
with NFT formation in tauopathies [29]. HDAC6 disrupts
this cascade by potentiating Par-1/MARK2-mediated
phosphorylation of KXGS motifs (detected by the 12E8
antibody), an effect that is eliminated by pseudoacetyla-
tion of KXGS motifs [11]. In addition, our recent findings
indicate that HDAC6 directly modulates tau polymerization
and acetylation, and this relationship is dependent on
the ability of HDAC6 to deacetylate tau specifically on
KXGS motifs [11]. These results support the hypothesis
that decreased HDAC6 activity increases acetylation of
KXGS motifs and, in so doing, prevents phosphorylation
of serine residues within the same motif. As acetylation
and phosphorylation of KXGS motifs act in a competitive
manner, and phosphorylation of KXGS motifs generates a
p-tau species that is resistant to degradation, future studies
will be required to determine whether acetylation of tau
on KXGS motifs impacts the ability of the chaperone
network to recognize tau in a similar manner to phos-
phorylation on these sites. Given that progressive hypoa-
cetylation and hyperphosphorylation of KXGS motifs is
observed in rTg4510 mice with aging [11], the fact that
tau turnover also decreases with aging in rTg4510 mice
[43] may indicate that the relationship between acetyl-
ation and phosphorylation on KXGS motifs regulates tau
turnover. The effects of other post-translational modifi-
cations on tau turnover are unknown; thus, it remains to
be determined whether differentially modified tau species
are degraded by the same mechanisms as hyperpho-
sphorylated tau, or if they are preferentially targeted to
alternative degradation pathways.
While hyperphosphorylated tau is ubiquitinated in
patients with AD [38,44] (Figure 1), indicating that
pathological tau species may be successfully targeted
for degradation, the accumulation of ubiquitinated tau
species in those patients suggests dysfunction of either
proteasomal or lysosomal degradation pathways con-
tributes to NFT formation in disease. The fact that ubi-
quitination and acetylation both modify lysine residues
indicates that these post-translational modifications
most likely compete to modify specific residues. Given
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[38,44], it is possible that excessive ubiquitination of tau
actually prevents acetylation, exacerbating tau aggregation.
The notion that excessive ubiquitination of tau may be
detrimental in tauopathies is somewhat counterintuitive.
However, as NFTs are composed of ubiquitinated tau, it is
clear that a failure of the cell to ubiquitinate tau is not the
root cause of tau accumulation. Thus, strategies to further
enhance ubiquitination of tau are not likely to promote
tau clearance in disease, indicating that different and
potentially unconventional approaches will need to be
considered in designing therapeutic strategies of the future.
Specifically, recent evidence indicates that acetylation of
tau on KXGS motifs under conditions of HDAC6 inhib-
ition not only prevents aggregation, but also blocks
phosphorylation on this same motif, thereby favoring
tau clearance [11]. In addition, reports that KXGS motifs
in tau species purified from NFTs are ubiquitinated
[38,42] indicate that these KXGS motifs are not acetylated,
consistent with the notion that tau species modified by
acetylation on KXGS motifs do not aggregate into NFTs.
As such, rather than developing strategies to enhance tau
ubiquitination in an effort to facilitate clearance, strategies
to promote tau acetylation specifically on KXGS motifs
could be evaluated for therapeutic efficacy.
Loss of HDAC6 alleviates defects in tau and
amyloid precursor protein models
Based on recent evidence that HDAC6 regulates tau
acetylation on KXGS motifs, it is of particular interest
that, in a Drosophila model of tauopathy, loss of HDAC6
activity rescued tau-induced microtubule defects in both
neuronal and muscle cells [45]. This finding provides the
first in vivo evidence that reducing HDAC6 activity in a
model of tauopathy is protective. Further emphasizing
the therapeutic potential of HDAC6 inhibitors are re-
sults demonstrating that loss of HDAC6 expression/
activity is also neuroprotective in other neurodegenera-
tive diseases, including AD, Huntington’s disease and
amyotrophic lateral sclerosis [46-48]. For instance, in a
mouse model of AD, genetic ablation of HDAC6 alleviated
cognitive impairment without impacting plaque burden,
which may suggest that beneficial consequences of loss
of HDAC6 expression are due to effects on endogenous
tau, though this has not yet been assessed in this model
[47]. Deletion of HDAC6 in a mouse model of mutant
superoxide dismutase 1-linked amyotrophic lateral scler-
osis is also neuroprotective, as reflected by the extended
life span of mice and increased motor axon integrity [48].
Several groups have demonstrated that loss of HDAC6
activity rescues impaired mitochondrial trafficking along
microtubules [47,49,50], most likely through enhanced
tubulin acetylation, providing additional insight into the
mechanisms by which HDAC6 inhibition enhancesneuronal survival. In particular, tubulin acetylation has
been shown to enhance the recruitment of molecular
motors kinesin-1 and dynein [46], thus facilitating an-
terograde and retrograde transport along the microtubu-
lar network [50,51]. The decrease in tubulin acetylation
and increased HDAC6 observed in patients with AD and
other tauopathies is indicative of a disrupted microtubular
network, which would be expected to contribute to the
pathophysiological changes associated with disease pro-
gression [50,52,53]. Another recent report identified a
decrease in microtubule stability in rTg4510 mice [54],
and also verified that treatment with the microtubule-
stabilizing compound epothilone D (EpoD) decreased
tau burden and cognitive deficits [54]. Zhang and col-
leagues [55] also reported that treatment with EpoD
not only effectively decreased tau pathology in another
tau transgenic mouse model (PS19 mice), but also
increased axonal microtubular density. The improve-
ment of microtubular stability by EpoD subsequently
resulted in improved axonal transport and cognitive
performance as assessed by a battery of behavioral tests
[55]. Given that HDAC6 inhibition similarly augments
axonal transport through enhanced tubulin acetylation,
these findings suggest that reduced HDAC6 activity
would also decrease tau burden and cognitive deficits in
tauopathy.
The coordinated regulation of HDAC6-mediated tubulin
acetylation and tau acetylation on KXGS motifs may allow
for tight regulation of microtubule dynamics and axonal
transport. While tubulin acetylation is a marker of micro-
tubule stability [56], increased tau acetylation may allow
tau to dissociate from stabilized microtubules, providing
molecular motors greater access to microtubules and fa-
cilitating axonal transport. The dissociation of tau and
tubulin under conditions of enhanced microtubule stabil-
ity is supported by a recent study employing FRET tech-
nology and live cell imaging to monitor the tau/tubulin
interaction [57]. Conversely, conditions of heightened
HDAC6 activity presumably lead to enhanced deacetyla-
tion of both tubulin and tau, which may promote tau-
microtubule interactions, leading to increased microtubule
stability. Given that phosphorylation, which prevents
acetylation, within KXGS motifs has also been reported to
release tau from microtubules [36], this event would be
expected to uncouple the coordinated regulation of
tubulin and tau acetylation, further contributing to the
pathogenicity of this particular p-tau species. Overall,
these results further speak to the complexity associated
with the biology of the tau protein and underline how
minute, molecular dysfunctions can contribute to the tau
pathology observed in patients with AD and other tauopa-
thies. Moreover, these studies also highlight the pressing
need to better understand tau biology under physiological
as well as pathological conditions.
Note: This article is part of a series on Tau-based therapeutic
strategies edited by Leonard Petrucelli. Other articles in this
series can be found at http://alzres.com/series/tau_therapeutics.
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There is now considerable evidence supporting the
trans-cellular propagation and seeding of tau pathology
in a variety of in vitro and in vivo models, ultimately
demonstrating that extracellular tau filaments can be in-
ternalized by cells and function as seeds for the assembly
of intracellular filaments [58-63]. While the precise
mechanism(s) underlying trans-neuronal tau propaga-
tion has yet to be elucidated, recent work is beginning to
provide insight into this pathway. Wu and colleagues
[64] observe internalization of misfolded tau at the level
of both dendritic and axonal terminals in neurons, after
which pathologic tau species can be transported in either
the antero- or retrograde direction, thereby leading to
the spreading of pathology. In addition, injection of
brain material from mice that express human mutant
P301S tau into transgenic mice expressing human wild-
type tau (ALZ17 model) was sufficient to induce tau
pathology not only within, but also adjacent to, the in-
jection site along anatomically connected pathways [58].
Furthermore, injection of brain extracts from patients
with different tauopathies into either ALZ17 or non-
transgenic mice was not only sufficient to drive inclusion
formation, but actually effectively reproduced the classic
hallmark lesions of the specific tauopathy characteristic
of the inoculating brain extract [65]. These studies
provide additional support for the concept that patho-
logically altered tau species possess a remarkable self-
propagating and seeding capacity, and also indicate that
seeding-competent tau species are somehow different
and distinct across the class of tauopathies, such that the
inoculating material acts as an exact template in the new
host. The specific characteristics of pathological tau species
that define and determine seeding capacity remain to be
identified, and could be the result of a precise pattern of
post-translational modifications that differentially impact
conformation of the tau molecule and ultimately deter-
mine aggregate structure. Our recent findings, which
demonstrate that acetylation within tau’s KXGS motifs
generates a tau species that fails to polymerize [11],
suggests that augmenting acetylation of the KXGS
motifs would also decrease tau seeding capacity.
Conclusion
We review here the rationale supporting the utilization
of HDAC6 inhibition to enhance tau acetylation as a
novel therapeutic strategy for tauopathies. HDAC6 in-
hibitors simultaneously promote acetylation and prevent
phosphorylation of tau on KXGS motifs, thereby inter-
fering with tau’s propensity to aggregate. Decreasing
HDAC6 activity also enhances microtubule stability and
transport, which is expected to further stimulate neur-
onal function. As HDAC6 inhibitors are currently being
evaluated in clinical trials for oncology indications, datawill soon be available to assess the safety of pharmaco-
logic modulation of HDAC6 in humans, which could
expedite their repurposing for other diseases. Although
additional research is needed to fully elucidate the cellular
and molecular pathways associated with the neuroprotec-
tive consequences of HDAC6 inhibition, it is becoming
increasingly apparent that modulating HDAC6 activity
may offer a very promising avenue for the treatment of
AD and associated tauopathies.Abbreviations
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